Northwest Biotherapeutics
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$22.8M
-0.3
-0.08
$1.38M
105
Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. The company is headquartered in Bethesda, Maryland and currently employs 105 full-time employees. The company went IPO on 2001-12-14. The firm is focused on developing personalized immune therapies for cancer. The company has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The firm's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. The company has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.
Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. The company is headquartered in Bethesda, Maryland and currently employs 105 full-time employees. The company went IPO on 2001-12-14. The firm is focused on developing personalized immune therapies for cancer. The company has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The firm's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. The company has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.
Recently from Cashu
Northwest Biotherapeutics Expands Manufacturing Capacity with New Grade C Suite for DCVax® Therapies
Northwest Biotherapeutics Expands Manufacturing Capacity with New Grade C Suite Northwest Biotherapeutics, a biotechnology firm dedicated to developing DCVax® personalized immune therapies for solid t…
Northwest Biotherapeutics Expands Manufacturing with New Grade C Suite for Cancer Therapies
Northwest Biotherapeutics Advances Manufacturing Capabilities with New Grade C Suite Northwest Biotherapeutics (OTCQB:NWBO), a biotechnology firm dedicated to developing personalized immune therapies…
Northwest Biotherapeutics Acquires Advent BioServices to Enhance Manufacturing and Cancer Treatment
Northwest Biotherapeutics Expands Capabilities with Advent BioServices Acquisition Northwest Biotherapeutics, Inc. has successfully finalized its acquisition of Advent BioServices Ltd., a strategic mo…
Northwest Biotherapeutics (NWBO) Acquires Advent BioServices to Enhance Operational Efficiency and Growth
Northwest Biotherapeutics Expands Capabilities with Advent BioServices Acquisition Northwest Biotherapeutics, Inc. (NWBO), a biotechnology company dedicated to developing personalized immune therapies…